MedTrace Logo

A Study of Sintilimab Combined With Apatinib and Capecitabine in Advanced Hepatocellular Carcinoma

NCT04411706 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 46

Last updated 2020-06-24

No results posted yet for this study

Summary

This study aims to evaluate the efficacy and safety of Sintilimab (an Anti-PD-1 Inhibitor) combined with apatinib and capecitabine as first-line therapy in patients with advanced hepatocellular carcinoma.

Conditions

Interventions

DRUG

Sintilimab Combined With Apatinib and Capecitabine

Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle; Drug: Apatinib,250mg po qd, for continuous medication; Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;

Sponsors & Collaborators

  • Xin-Hua Xu

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-06-21
Primary Completion
2021-06-01
Completion
2022-06-01

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04411706 on ClinicalTrials.gov